Literature DB >> 17382779

Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction.

Tack Lee1, Petter Hedlund, Donald Newgreen, Karl-Erik Andersson.   

Abstract

PURPOSE: Prostaglandin E(2) and its EP(1) receptor were suggested as endogenous modulators of bladder function in the normal physiological state and under pathophysiological conditions. We investigated if the new EP(1) receptor antagonist PF-2907617-02 would influence the regulation of normal micturition in rats, and if it affects bladder function in animals with partial bladder outlet obstruction.
MATERIALS AND METHODS: The study was performed in normal female Sprague-Dawley rats and in rats with moderate, experimentally induced bladder outlet obstruction 2 weeks in duration. All animals underwent continuous cystometry in the awake state. PF-2907617-02 was given intravenously at doses of 0.1 and 1.0 mg/kg(-1) in normal rats, and at 1.0 mg/kg(-1) in bladder outlet obstructed animals. In a group of normal rats detrusor overactivity was produced by intravesical instillation of prostaglandin E(2).
RESULTS: In normal rats PF-2907617-02 (1 mg/kg(-1)) significantly increased bladder capacity, micturition volume and the micturition interval but it had no effect on other urodynamic parameters. The lower dose of PF-2907617 (0.1 mg/kg(-1)) showed no effect. Intravesical prostaglandin E(2) (50 muM) induced detrusor overactivity. The antagonist significantly decreased the stimulatory effects of prostaglandin E(2) at 0.1 and 1.0 mg/kg(-1). In obstructed animals PF-2907617-02 significantly increased the micturition interval but not bladder capacity and residual volume. The drug also decreased the frequency and amplitude of nonvoiding contractions.
CONCLUSIONS: EP(1) receptor is involved in initiation of the micturition reflex in normal rats and in animals with bladder outlet obstruction. It may also contribute to the generation of detrusor overactivity after bladder outlet obstruction. Thus, EP(1) receptor antagonists may have potential as treatment for detrusor overactivity in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382779     DOI: 10.1016/j.juro.2006.11.070

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Expression of E-series prostaglandin (EP) receptors and urodynamic effects of an EP4 receptor antagonist on cyclophosphamide-induced overactive bladder in rats.

Authors:  Yao-Chi Chuang; Naoki Yoshimura; Chao-Cheng Huang; Moya Wu; Pradeep Tyagi; Michael B Chancellor
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

Review 2.  Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.

Authors:  Emilio Sacco; Francesco Pinto; Pierfrancesco Bassi
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-15

Review 3.  Urothelial signaling.

Authors:  Lori Birder; Karl-Erik Andersson
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

4.  Prostaglandin E2 induces spontaneous rhythmic activity in mouse urinary bladder independently of efferent nerves.

Authors:  S Kobayter; J S Young; K L Brain
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist.

Authors:  Wesam Bassiouni; Tahia Daabees; Xavier Norel; Amira M Senbel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-14       Impact factor: 3.000

6.  The role of prostaglandin and E series prostaglandin receptor type 4 receptors in the development of bladder overactivity in a rat model of chemically induced prostatic inflammation.

Authors:  Shinsuke Mizoguchi; Amanda S Wolf-Johnson; Jianshu Ni; Kenichi Mori; Takahisa Suzuki; Eiichiro Takaoka; Hiromitsu Mimata; Donald B DeFranco; Zhou Wang; Lori A Birder; Naoki Yoshimura
Journal:  BJU Int       Date:  2019-06-26       Impact factor: 5.588

Review 7.  Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?

Authors:  Emilio Sacco; Riccardo Bientinesi
Journal:  Int Urogynecol J       Date:  2014-11-07       Impact factor: 2.894

Review 8.  The role of prostanoids in urinary bladder physiology.

Authors:  Mohammad S Rahnama'i; Philip E V van Kerrebroeck; Stefan G de Wachter; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2012-03-13       Impact factor: 14.432

9.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

10.  Dual modulation of urinary bladder activity and urine flow by prostanoid EP3 receptors in the conscious rat.

Authors:  M J Jugus; J P Jaworski; P B Patra; J Jin; D M Morrow; N J Laping; R M Edwards; K S Thorneloe
Journal:  Br J Pharmacol       Date:  2009-05-22       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.